Atlas Trials

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Clinical trial NCT06430827 · UNKNOWN

Trial details

NCT number
NCT06430827
Sponsor
Ba Yi
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract Carcinoma
Start date
2024-06-30
Primary completion
2024-12-31
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.